Steminent Biotherapeutics Inc. (TPEX:7729)

Market Cap	4.61B +286.7%
Revenue (ttm)	n/a
Net Income	-174.04M
EPS	-2.95
Shares Out	66.63M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	487,721
Open	68.80
Previous Close	69.50
Day's Range	67.10 - 69.60
52-Week Range	19.55 - 95.60
Beta	0.39
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 17, 2026

About Steminent Biotherapeutics

Steminent Biotherapeutics Inc. operates as a biopharmaceutical company in Taiwan and the United States. It offers Stemchymal, a cell therapy product for the treatment of neurodegenerative diseases, including spinocerebellar ataxia and huntington’s disease; tissue regeneration, such as osteoarthritis; and acute syndromes comprising acute respiratory distress syndrome, liver failure, and ischemic stoke. The company was founded in 2009 and is based in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7729